Analyst Expectations for PTC Therapeutics's Future
Portfolio Pulse from Benzinga Insights
PTC Therapeutics (NASDAQ:PTCT) has received mixed analyst ratings in the last quarter, with 2 bullish, 1 somewhat bullish, 7 indifferent, 1 somewhat bearish, and 2 bearish ratings. The average 12-month price target among 13 analysts is $30.23, which is a 27.85% decrease from the previous target of $41.90. Ratings suggest a cautious outlook on the stock.
November 20, 2023 | 3:00 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
PTC Therapeutics has a new average price target of $30.23, reflecting a significant decrease from the previous target, indicating a cautious stance from analysts.
The decrease in the average price target suggests that analysts have become more bearish on PTC Therapeutics' future performance. This could lead to a negative short-term impact on the stock price as investors adjust their expectations.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100